This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Galena's Breast Cancer Vaccine Doomed to Fail

Think about it, if Roche was really interested in NeuVax, it could have bought Apthera, the original owner of the vaccine, for $7 million. That's the price Galena paid to acquire the tiny, private company last year.

For Roche, $7 million is not even a rounding error on a rounding error on a rounding error on the company's balance sheet. Roche's involvement in this phase II combination study is scientific charity, not serious R&D due diligence. I'm sure someone inside Roche performed the same analysis I just did and reached a similar conclusion.

Second, Galena bulls often ask: Why would Galena buy Apthera if NeuVax wasn't legitimate?

Galena bought Apthera for a lousy $7 million because the company was desperate to stay in business following the collapse of its original mission to develop drugs based on RNA interference, or RNAi. Biotech companies don't fold voluntarily and return money to shareholders when their business plans flop, so RXi Pharmaceuticals ditched RNAi, bought Apthera and changed its name to Galena Biopharma.

An RNAi company was now transformed into a cancer immunotherapy company… like magic!

Apthera had been a ghost company for years -- unwanted by anyone in the bio-pharma industry. Some of the initial phase II NeuVax data in breast cancer was first presented and published in 2005. In 2009, Apthera landed the SPA with the FDA for the phase III study (it took 21 months to negotiate) but the company had no money to actually start the study.

Experimental therapies with blockbuster potential don't sit on a shelf for years by accident. They're noticed and bought. NeuVax is not one of these exciting, lucrative therapies. It sat unloved because the data generated from the phase II study don't justify further development.

I'm sure the management team inside RXi/Galena knows this, but they're certainly not going to divulge NeuVax's dirty little secret because they need retail investors continue buying the stock.

With three more years at least before NeuVax fails, Galena management has a lot more stock to sell and millions of dollars in paychecks to cash.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
3 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,119.57 -53.11 -0.31%
S&P 500 1,991.31 -2.98 -0.15%
NASDAQ 4,530.4470 +2.7580 0.06%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs